Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

THC Biomed Intl Ltd C.THC

Alternate Symbol(s):  THCBF

THC Biomed Intl Ltd. is a Canada-based cannabis producer. The Company’s principal business is the production and sale of cannabis through THC BioMed Ltd., which is a small batch Licensed Producer as regulated by the Cannabis Act which regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company’s biological assets consist of cannabis plants (mother plants and clones for growth); resin; oil; harvested marijuana flowers prior to completion of the drying, grading and testing processes; and edible concentrate. The Company operates in a single reportable segment being the cultivation and sale of cannabis. Its subsidiaries include THC BioMed Ltd., Clone Shipper Ltd., THC BioMed Victoria Falls Ltd., THC2GO Dispensaries Ltd. (THC2GO), and THC BioMed Lesotho Ltd. (THC Lesotho). Clone Shipper Ltd. owns all rights to the Clone Shipper product used to transport live plants.


CSE:THC - Post by User

Post by Greencashon Nov 03, 2020 8:24am
113 Views
Post# 31828573

Pot-induced headache worsening at big banks: analyst

Pot-induced headache worsening at big banks: analysthttps://ca.finance.yahoo.com/news/potinduced-headache-worsening-at-big-banks-analyst-154311852.html

Pot-induced headache worsening at big banks: analyst

Jeff Lagerquist
·2 mins read
 
 

More cannabis companies are testing the patience of the big banks, according to a credit expert who sees a growing number of producers failing to meet covenants on their debt.

On Thursday, HEXO (HEXO.TO)(HEXO) became the latest major Canadian pot company to run afoul of terms imposed by lenders. The company reported quarterly net revenue of $27.1 million, falling just shy of the $28.4 million required to draw on a $15 million term loan from a syndicated credit facility led by CIBC and Bank of Montreal. According to financial filings, those funds are no longer available to the company.

Craig Wiggins, managing director of The Cannalysts, an independent cannabis research firm, sees an accelerating trend in a sector already beset by scarce capital. Separate from his cannabis research, Wiggins worked for more than 30 years in credit-related roles, including at HSBC, where he audited large commercial portfolios.

“Credit fatigue has probably set in across the banks,” he said in an interview.

“When I was at a bank, it would be called ‘special credit’ or ‘special loans,’ where these files would be essentially taken away from the commercial centre because there are so many covenant changes and violations. I have to imagine almost the entire cannabis portfolios of some of these banks are residing there.”

CIBC and Bank of Montreal did not immediately respond to a request for comment about loans to cannabis companies.

Wiggins lists Sundial Growers (SNLD), Organigram (OGI.TO)(OGI), Aurora Cannabis (ACB.TO)(ACB) and WeedMD (WMD.V) among the pot producers that have breached loan covenants.

He points to Moncton-based Organigram’s recently amended credit facilities with Bank of Montreal as evidence of lenders reacting to risk in the sector with stricter terms for borrowers.

Organigram said in May that funds raised by the company after Dec. 31, 2020 are required to be used to repay the $115 million term loan and $25 million revolving line of credit, subject to certain exceptions.

“The money Organigram would be raising from new investors isn’t going to increase the size of the business. It’s going to repay existing debt,” Wiggins said.

“What we’re seeing is a transfer of wealth from companies and shareholders to lenders,” he added. “Banks hate losing money. They’ll do anything not to lose money.”

Jeff Lagerquist is a senior reporter at Yahoo Finance Canada. Follow him on Twitter @jefflagerquist.

Download the Yahoo Finance app, available for Apple and Android.


<< Previous
Bullboard Posts
Next >>